Clinical Trial Detail

NCT ID NCT02581787
Title SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Maximilian Diehn
Indications

lung non-small cell carcinoma

Therapies

Fresolimumab

Age Groups: adult

No variant requirements are available.